Trial Profile
An open-label, randomized, crossover study assessing Pharmacokinetics and safety of transdermal and oral granisetron in healthy Chinese subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Oct 2018
Price :
$35
*
At a glance
- Drugs Granisetron (Primary) ; Granisetron
- Indications Chemotherapy-induced nausea and vomiting
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Solasia Pharma
- 29 Oct 2018 New trial record
- 19 Oct 2018 Results published in the International Journal of Clinical Pharmacology and Therapeutics